You are here: Industry Insights > Merck

News List

Merck secures FDA expanded indication for Zerbaxa pharmaceutical-technology
June 05, 2019
The US Food and Drug Administration (FDA) has approved Merck’s antibiotic Zerbaxa to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and above.
Years after Cubist buyout, Merck scores a new Zerbaxa indication. Can it jump-start sales? fiercepharma
June 05, 2019
Merck hasn’t exactly made a fortune on its $9.5 billion Cubist Pharmaceuticals buyout, but now, a next-generation antibiotic it acquired in that deal has a brand-new indication that could help jump-start sales.
Merck pioneers new effort to see MS from the inside out worldpharmanews
May 31, 2019
Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple Sclerosis International Federation (MSIF) to ...
Merck’s threat to Pfizer’s lucrative prevnar brand gains ground with positive Phase II results pharmaceutical-technology
May 23, 2019
US drug company Merck and Co Inc. released Phase II trial results on 8 May for its investigational 15-valent conjugate pneumococcal vaccine, V114, which showed overall non-inferiority to ...
Merck signs $1bn deal to buy Peloton Therapeutics pharmaceutical-technology
May 23, 2019
Merck has signed a definitive agreement to acquire biopharmaceutical company Peloton Therapeutics for an upfront payment of $1.05bn.
Merck to Acquire Peloton Therapeutics americanpharmaceuticalreview
May 22, 2019
Merck and Peloton Therapeutics announced the companies have entered into a definitive agreement under which Merck, throu
Merck joins TRANSVAC2 programme to advance vaccine development biospectrumasia
May 21, 2019
TRANSVAC2, part of the EU's Horizon 2020 program, provides trainings to streamline vaccine manufacturing and development
Pfizer & Merck's Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer pharmafile
May 16, 2019
The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC).
As Merck Ebola vaccine runs short in Congo, WHO looks to J&J experimental drug fiercepharma
May 12, 2019
With an Ebola outbreak in Congo outrunning vaccination efforts to control it and the supplies of Merck’s Ebola vaccine on hand, the World Health Organization has revamped its plan of attack.
Merck's Gardasil blockbuster sales prompt $1B plant expansion fiercepharma
May 09, 2019
Merck & Co. has been experiencing a surging wave of Gardasil sales that it expects to ride for some time yet. To maintain the momentum, the drugmaker says it will spend $1 billion to expand production.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page